AffiliationDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
MetadataShow full item record
AbstractHypoxia is a feature of most solid tumours and is associated with a poor prognosis. The hypoxic environment can reduce the efficacy of radiotherapy and some chemotherapeutics, and has been investigated extensively as a therapeutic target. The clinical use of hypoxia-targeting treatment will benefit from the development of a biomarker to assess tumour hypoxia. There are several possible techniques that measure either the level of oxygen or the tumour molecular response to hypoxia. The latter includes gene expression profiling, which measures the transcriptional response of a tumour to its hypoxic microenvironment. A systematic review identified 32 published hypoxia gene expression signatures. The methods used for their derivation varied, but are broadly classified as: (i) identifying genes with significantly higher or lower expression in cancer cells cultured under hypoxic versus normoxic conditions; (ii) using either previously characterised hypoxia-regulated genes/biomarkers to define hypoxic tumours and then identifying other genes that are over- or under-expressed in the hypoxic tumours. Both generated gene signatures useful in furthering our understanding of hypoxia biology. However, signatures derived using the second method seem to be superior in terms of providing prognostic information. Here we summarise all 32 published hypoxia signatures, discuss their commonalities and differences, and highlight their strengths and limitations. This review also highlights the importance of reproducibility and gene annotation, which must be accounted for to transfer signatures robustly for clinical application as biomarkers.
CitationGene expression signatures as biomarkers of tumour hypoxia. 2015, 27 (10):547-60 Clin Oncol
- Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia.
- Authors: Haider S, McIntyre A, van Stiphout RG, Winchester LM, Wigfield S, Harris AL, Buffa FM
- Issue date: 2016 Jun 29
- Impact of supervised gene signatures of early hypoxia on patient survival.
- Authors: Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, Evelo CT, Begg AC, Wouters BG, Lambin P
- Issue date: 2007 Jun
- The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer.
- Authors: Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, Koritzinsky M, Kasprzyk A, Boutros PC, Wouters BG, Lambin P
- Issue date: 2012 Mar
- Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy.
- Authors: Toustrup K, Sørensen BS, Alsner J, Overgaard J
- Issue date: 2012 Apr
- In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer.
- Authors: Abu-Jamous B, Buffa FM, Harris AL, Nandi AK
- Issue date: 2017 Jun 15